ATE327242T1 - Neue purine - Google Patents

Neue purine

Info

Publication number
ATE327242T1
ATE327242T1 AT00986551T AT00986551T ATE327242T1 AT E327242 T1 ATE327242 T1 AT E327242T1 AT 00986551 T AT00986551 T AT 00986551T AT 00986551 T AT00986551 T AT 00986551T AT E327242 T1 ATE327242 T1 AT E327242T1
Authority
AT
Austria
Prior art keywords
purines
new
new purines
cancer
compounds
Prior art date
Application number
AT00986551T
Other languages
English (en)
Inventor
Manfred Weigele
William Shakespeare
Tomi K Sawyer
Rajeswari Sundaramoorthi
Regine Bohacek
Yihan Wang
Chester A Metcalf Iii
David C Dalgarno
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Priority claimed from US09/740,267 external-priority patent/US20020103161A1/en
Application granted granted Critical
Publication of ATE327242T1 publication Critical patent/ATE327242T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548Phosphates or phosphonates, e.g. bone-seeking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • C07F9/4012Esters of acyclic acids which can have further substituents on alkyl substituted by B, Si, P or a metal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025Esters of poly(thio)phosphonic acids
    • C07F9/405Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT00986551T 1999-12-17 2000-12-18 Neue purine ATE327242T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17251099P 1999-12-17 1999-12-17
US17216199P 1999-12-17 1999-12-17
US24078800P 2000-10-16 2000-10-16
US09/740,267 US20020103161A1 (en) 1999-12-17 2000-12-18 Novel heterocycles
US09/740,619 US6420384B2 (en) 1999-12-17 2000-12-18 Proton pump inhibitors

Publications (1)

Publication Number Publication Date
ATE327242T1 true ATE327242T1 (de) 2006-06-15

Family

ID=27538855

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00986551T ATE327242T1 (de) 1999-12-17 2000-12-18 Neue purine

Country Status (7)

Country Link
EP (1) EP1259520B1 (de)
JP (1) JP2004501062A (de)
AT (1) ATE327242T1 (de)
CA (1) CA2394646A1 (de)
DE (1) DE60028253T2 (de)
IL (1) IL150060A0 (de)
WO (1) WO2001044260A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1377579T3 (da) * 2000-10-31 2009-08-31 Aventis Pharma Inc Acyl- og sulfonylderivater af 6,9-disubstitueret-2(trans-1,4-diaminocyklohexyl)puriner og deres anvendelse som antiproliferative midler
WO2006136005A1 (en) * 2005-05-16 2006-12-28 Prometic Biosciences Inc. Purine derivatives and their use for treatment of autoimmune diseases
JP5321061B2 (ja) * 2005-08-11 2013-10-23 アリアド・ファーマシューティカルズ・インコーポレイテッド 不飽和複素環誘導体
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
JP4517078B2 (ja) * 2005-08-30 2010-08-04 独立行政法人産業技術総合研究所 新規ビスホスフィノイル化合物、その製造方法及びそれを有効成分とした医薬
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
EP2700638A1 (de) * 2006-05-31 2014-02-26 The Regents Of the University of California Purinanaloga
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
EP2144911A2 (de) 2007-03-28 2010-01-20 NeuroSearch AS Purinylderivate und ihre verwendung als kaliumkanalmodulatoren
US8268838B2 (en) 2008-09-26 2012-09-18 Neurosearch A/S Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CA2743449C (en) 2008-11-12 2016-10-18 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
US9475797B2 (en) 2012-06-26 2016-10-25 Saniona A/S Phenyl triazole derivative and its use for modulating the GABAA receptor complex
WO2014124458A1 (en) 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
ES2919024T3 (es) * 2014-02-11 2022-07-21 Mitokinin Inc Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
AU2018290225A1 (en) 2017-06-21 2020-01-23 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1017564B (it) * 1974-04-30 1977-08-10 Snam Progetti Processo per la preparazione di derivati adeninici funzionalizza ti e prodotti cosi ottenuti
US5688778A (en) * 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
CA2297294C (en) * 1989-05-15 2005-11-08 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxymethylpurine/pyrimidine derivatives
GB9020932D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
EP0531597A1 (de) * 1991-09-12 1993-03-17 Merrell Dow Pharmaceuticals Inc. Ungesättigte azyklische Phosphonsäure Purinderivats und Pyrimidinderivate
US5849905A (en) * 1994-11-23 1998-12-15 Centre National De La Recherche Scientifique Biologically active phosphotriester-type nucleosides and methods for preparing same
CA2224710A1 (en) * 1995-06-15 1997-01-03 Naoko Inoue Phosphonate nucleotide derivatives
BR9712285A (pt) * 1996-10-09 2001-11-20 Pharmasset Ltd Tetrafosfonato bicìclico de trianidridas
US6284748B1 (en) * 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase

Also Published As

Publication number Publication date
CA2394646A1 (en) 2001-06-21
WO2001044260A2 (en) 2001-06-21
EP1259520A2 (de) 2002-11-27
DE60028253T2 (de) 2007-03-08
JP2004501062A (ja) 2004-01-15
IL150060A0 (en) 2002-12-01
WO2001044260A9 (en) 2002-07-04
EP1259520B1 (de) 2006-05-24
WO2001044260A3 (en) 2002-01-03
DE60028253D1 (de) 2006-06-29
WO2001044260A8 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
ATE327242T1 (de) Neue purine
NZ508268A (en) Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation
IL151132A0 (en) Pteridine compounds for the treatment of psoriasis
ATE309223T1 (de) Cyclin-abhängige kinase inhibitoren
BR9408407A (pt) Uso de inibidores pla2 como tratamento para doença de alzheimer
DK1914237T3 (da) Antivirale fosfonatesterforbindelser
NO984718L (no) Irreversible inhibitorer for tyrosin-kinaser
JO2248B1 (en) Pirazolobenzodiazepines
ATE250063T1 (de) Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
NO20005885L (no) Kombinasjonsterapi for behandling av refraktær depresjon
DK1716853T3 (da) Behandling af cancer i menneskekroppen ved anvendelse af ET743
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
ATE242234T1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
YU55200A (sh) Supstituisani bisindolmaleimidi za inhibiranje ćelijske proliferacije
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
BR0012921A (pt) Compostos calcilìticos
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
IT1278858B1 (it) Strumentario per il trattamento di fratture articolari della caviglia
IL139144A0 (en) Mycobacterial inhibitors
DE19983519T1 (de) Vorrichtung zur Wärmebehandlung von Körpergewebe
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
ID24922A (id) Terapi kombinasi untuk pengobatan aids
AU2184202A (en) Imidazolone derivatives for the treatment of viral diseases
EP1135141A4 (de) Phospholipase inhibitoren zur behandlung von krebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties